The FNIH Announces $4M Grant Award to Support Building of First International Arm of AMP Type 2 Diabetes Knowledge Portal

The Foundation for the National Institutes of Health (FNIH) has awarded a 4-year grant award in the amount of $4 million to the European Molecular Biology Laboratory — European Bioinformatics Institute (EMBL‐EBI), the University of Oxford, and the Broad Institute of the Massachusetts Institute of Technology and Harvard University to support the buildout of a European arm of the Type 2 Diabetes (T2D) Knowledge Portal. The award is part of the Accelerating Medicines Partnership Type 2 Diabetes (AMP T2D) initiative. This is the first in what the project hopes to be a buildout of a broader network of interconnected, international portal sites.

The AMP T2D Knowledge Portal is a sophisticated research tool that allows the public to search and analyze genetic and clinical information on individuals with type 2 diabetes and serious complications of the disease, while maintaining strict confidentiality of individual level data. The Knowledge Portal is intended to generate new understanding of the disease by revealing relationships between human genome-wide sequence variation in potential targets and either risk for or protection from diabetes and its complications. The portal is planned to contain data integrated from existing genetic studies from close to 100,000 individuals by early 2016.

In June 2015, the FNIH issued a Request for Proposals (RFP), which solicited applications to build and maintain secure, distributed database hubs for the project’s Knowledge Portal outside of the United States. Establishing one or more new hubs outside of the United States allows researchers to store their data at any of the portal’s hubs and enables analyses across global datasets while maintaining compliance with regional data privacy regulations. This FNIH award funds the buildout of a European hub, based in the United Kingdom, over the 4 year period. AMP T2D hopes to expand this pilot hub to various other international federated sites that could allow participation from groups on any continent.

The portal’s U.S. hub resides at the Broad Institute in Cambridge, MA, and is funded by a grants from both the National Institute on Digestive and Kidney Disease (NIDDK)/National Institutes of Health (NIH) and the FNIH.

Funding Partners:

American Diabetes Association, Janssen Research and Development LLC, JDRF International, Eli Lilly and Company, Merck Sharp & Dohme Corp., NIDDK/NIH, Pfizer Inc., and Sanofi US Services.

About the Accelerating Medicines Partnership:

A public private partnership that brings together NIH, biopharmaceutical companies, and not-for-profit organizations, AMP’s mission is to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of disease. AMP’s goal is to generate diverse, high quality, pre-competitive, disease-specific clinical data to be made publicly available for the purpose of accelerating drug development. The FNIH raises and distributes private sector funds for AMP, provides central project management to AMP initiatives, and convenes the governing committees that oversee the partnership on behalf of all the stakeholders. Read more about the AMP T2D initiative


Front Page: